Current Situation of Methamphetamine Abuse and Related Research Progress

doi:10.12116/j.issn.1004-5619.2021.310202

Abstract

Abstract:

Drug problem is a major social and public security problem in the world. Drug abuse poses a great threat to economic development, social stability and public health. In recent years, synthetic drugs represented by methamphetamine have surpassed traditional drugs such as morphine, heroin, ketamine and become one of the most abused drugs in the world. In order to solve the problem of drug abuse, it is of great theoretical value and practical significance to carry out all-round and multi-level scientific research on drug-related issues. Based on the current situation of drug abuse, this article reviews research progresses on the epidemiology of methamphetamine abuse, the monitoring technology, the basic researches on toxicity damage, the withdrawal drug screening, the related clinical comorbidity and the testing technologies, comprehensively presenting the development trend of methamphetamine abuse related issues.

Key words: forensic toxicology, addiction, methamphetamine, substance abuse, comorbidity, review

CLC Number:

DF795.1

Shi-jun HONG, Bao-yu SHEN, Rong-ji SUN, Gen-meng YANG, Chun-mei DUAN, Qian-yun NIE, Cong-bin ZHANG, Wen-juan DONG, Hao YU, Shang WANG, Peng-liang LIU, Pin-yuan WEN, Li-hua LI. Current Situation of Methamphetamine Abuse and Related Research Progress[J]. Journal of Forensic Medicine, 2021, 37(6): 763-775.

References 132

1	United Nations Office on Drugs and Crime （UNODC）. World drug report 2021[EB/OL]. （2021-06-24）[2021-12-29]. .
2	2020年中国毒情形势报告[EB/OL].（2021-07-16）[2021-12-29]. .
	Drug situation in China （2020）[EB/OL]. （2021-07-16）[2021-12-29]. .
3	KOHNO M， BESTE C， PILHATSCH M. Editorial： The global methamphetamine problem： Approaches to elucidate the neurobiology， epidemiology， and therapeutic effectiveness[J]. Front Psychiatry，2020，11：850. doi：10.3389/fpsyt.2020.00850.
4	SPIVAK B， SHEPHERD S， BORSCHMANN R， et al. Crystalline methamphetamine （ice） use prior to youth detention： A forensic concern or a public health issue?[J]. PLoS One，2020，15（5）：e0229389. doi：10.1371/journal.pone.0229389.
5	王延涛. 新冠疫情中境外毒品交易的变化及应对措施[J].犯罪与改造研究，2020（12）：2.
	WANG Y T. Changes and countermeasures of overseas drug trade during the COVID-19 pandemic[J]. Fanzui Yu Gaizao Yanjiu，2020（12）：2.
6	DAUGHTON C G. Pharmaceuticals and personal care products in the environment： Scientific and regulatory issues[M]. Washington， D.C.： American Chenmical Society，2001：348-364.
7	原帅，向平，于治国，等. 污水中毒品分析方法研究进展[J].中国司法鉴定，2020（4）：23-30. doi：10.3969/j.issn.1671-2072.2020.04.004.
	YUAN S， XIANG P， YU Z G， et al. Advances in the determination of illicit drugs in wastewater[J]. Zhongguo Sifa Jianding，2020（4）：23-30.
8	GONZÁLEZ-MARIÑO I， BAZ-LOMBA J A， ALY-GIZAKIS N A， et al. Spatio-temporal assessment of illicit drug use at large scale： Evidence from 7 years of international wastewater monitoring[J]. Addiction，2020，115（1）：109-120. doi：10.1111/add.14767.
9	LAI F Y， O’BRIEN J， THAI P K， et al. Trends in methamphetamine residues in wastewater in metropolitan and regional cities in south-east Queensland，2009-2015[J]. Med J Aust，2016，204（4）：151-152. doi：10.5694/mja15.01054.
10	WILKINS C， LAI F Y， O’BRIEN J， et al. Comparing methamphetamine， MDMA， cocaine， codeine and methadone use between the Auckland region and four Australian states using wastewater-based epidemiology （WBE）[J]. N Z Med J，2018，131（1478）：12-20.
11	KIM K Y， LAI F Y， KIM H Y， et al. The first application of wastewater-based drug epidemiology in five South Korean cities[J]. Sci Total Environ，2015，524/525：440-446. doi：10.1016/j.scitotenv.2015.04.065.
12	ZAREI S， SALIMI Y， REPO E， et al. A global systematic review and meta-analysis on illicit drug consumption rate through wastewater-based epide-miology[J]. Environ Sci Pollut Res Int，2020，27（29）：36037-36051. doi：10.1007/s11356-020-09818-6.
13	吕宪祥，曾岚，刘志民，等. 药物滥用监测与监测数据分析[J].中国药理学与毒理学杂志，1997，11（2）：157-158.
	LÜ X X， ZENG L， LIU Z M， et al. Drug abuse monitoring and data analysis[J]. Zhongguo Yaolixue Yu Dulixue Zazhi，1997，11（2）：157-158.
14	LAI F Y， BRUNO R， LEUNG H W， et al. Estimating daily and diurnal variations of illicit drug use in Hong Kong： A pilot study of using wastewater analysis in an Asian metropolitan city[J]. Forensic Sci Int，2013，233（1/2/3）：126-132. doi：10.1016/j.forsciint.2013.09.003.
15	KHAN U， NUIJS A L N VAN， LI J， et al. Application of a sewage-based approach to assess the use of ten illicit drugs in four Chinese megacities[J]. Sci Total Environ，2014，487：710-721. doi：10.1016/j.scitotenv.2014.01.043.
16	孙荣基，吴天辉，孟怡然，等. 通过污水分析估计昆明市的甲基苯丙胺滥用情况[J].中国药物滥用防治杂志，2019，25（6）：317-321. doi：10.15900/j.cnki.zylf1995.2019.06.002.
	SUN R J， WU T H， MENG Y R， et al. Estimation of methamphetamine use in Kunming by wastewater analysis[J]. Zhongguo Yaowu Lanyong Fangzhi Zazhi，2019，25（6）：317-321.
17	SHAO X T， LIU Y S， TAN D Q， et al. Methamphetamine use in typical Chinese cities evaluated by wastewater-based epidemiology[J]. Environ Sci Pollut Res Int，2020，27（8）：8157-8165. doi：10.1007/s11356-019-07504-w.
18	DU P， LI K， LI J， et al. Methamphetamine and ketamine use in major Chinese cities， a nationwide reconnaissance through sewage-based epidemiology[J]. Water Res，2015，84：76-84. doi：10.1016/j.watres.2015.07.025.
19	王强. 环境污水监测技术对深圳基层毒品防控的借鉴及启示[J].环境科学与管理，2019，44（5）：113-117. doi：10.3969/j.issn.1673-1212.2019.05.027.
	WANG Q. Application and enlightenment of environmental sewage monitoring technique to grassroots illicit drugs prevention and control[J]. Huanjing Kexue Yu Guanli，2019，44（5）：113-117.
20	杨根梦，陈逊，曾晓锋. 甲基苯丙胺诱导神经细胞自噬的研究进展[J].中国药理学通报，2016，32（10）：1341-1344. doi：10.3969/j.issn.1001-1978.2016.10.003.
	YANG G M， CHEN X， ZENG X F. Research progress of methamphetamine inducing nerve cell’s autophagy[J]. Zhongguo Yaolixue Tongbao，2016，32（10）：1341-1344.
21	CRUICKSHANK C C， DYER K R. A review of the clinical pharmacology of methamphetamine[J]. Addiction，2009，104（7）：1085-1099. doi：10.1111/j.1360-0443.2009.02564.x.
22	刘溪，代振凤，蒲小平. 甲基苯丙胺成瘾机制进展[J].中国新药杂志，2017，26（21）：2541-2545.
	LIU X， DAI Z F， PU X P. Advances in the mechanism of methamphetamine addiction[J]. Zhongguo Xinyao Zazhi，2017，26（21）：2541-2545.
23	翁传波，钱若兵，傅先明. 甲基苯丙胺成瘾机制的研究进展[J].国际神经病学神经外科学杂志，2012，39（1）：65-69. doi：10.16636/j.cnki.jinn.2012.01.022.
	WENG C B， QIAN R B， FU X M. Research progress on the mechanism of methamphetamine addiction[J]. Guoji Shengjingbingxue Shengjingwaike-xue Zazhi，2012，39（1）：65-69.
24	PIMENTEL E， SIVALINGAM K， DOKE M， et al. Effects of drugs of abuse on the blood-brain barrier： A brief overview[J]. Front Neurosci，2020，14：513. doi：10.3389/fnins.2020.00513.
25	HAWKINS B T， DAVIS T P. The blood-brain barrier/neurovascular unit in health and disease[J]. Pharmacol Rev，2005，57（2）：173-185. doi：10.1124/pr.57.2.4.
26	ABBOTT N J， RÖNNBÄCK L， HANSSON E. Astrocyte-endothelial interactions at the blood-brain barrier[J]. Nat Rev Neurosci，2006，7（1）：41-53. doi：10.1038/nrn1824.
27	郄晓娟. 甲基苯丙胺诱导血脑屏障损伤的内质网应激机制研究[D].石家庄：河北医科大学，2017.
	QIE X J. Endoplasmic reticulum mechanism in methamphetamine-induced blood-brain barrier[D]. Shijiazhuang： Hebei Medical University，2017.
28	XIAO N， ZHANG F， ZHU B， et al. CDK5-mediated tau accumulation triggers methamphetamine-induced neuronal apoptosis via endoplasmic reticulum-as-sociated degradation pathway[J]. Toxicol Lett，2018，292：97-107. doi：10.1016/j.toxlet.2018.04.027.
29	WONGPRAYOON P， GOVITRAPONG P. Melatonin protects SH-SY5Y neuronal cells against metham-phetamine-induced endoplasmic reticulum stress and apoptotic cell death[J]. Neurotox Res，2017，31（1）：1-10. doi：10.1007/s12640-016-9647-z.
30	CHEN C， QINCAO L， XU J， et al. Role of PUMA in methamphetamine-induced neuronal apoptosis[J]. Toxicol Lett，2016，240（1）：149-160. doi：10.1016/j.toxlet.2015.10.020.
31	PARK J H， SEO Y H， JANG J H， et al. Asiatic acid attenuates methamphetamine-induced neuroinflammation and neurotoxicity through blocking of NF-kB/STAT3/ERK and mitochondria-mediated apoptosis pathway[J]. J Neuroinflammation，2017，14（1）：240. doi：10.1186/s12974-017-1009-0.
32	XIONG K， LIAO H， LONG L， et al. Necroptosis contributes to methamphetamine-induced cytotoxi-city in rat cortical neurons[J]. Toxicol In Vitro，2016，35：163-168. doi：10.1016/j.tiv.2016.06.002.
33	FOROUGHI K， KHAKSARI M， RAHMATI M， et al. Apelin-13 protects PC12 cells against metham-phetamine-induced oxidative stress， autophagy and apoptosis[J]. Neurochem Res，2019，44（9）：2103-2112. doi：10.1007/s11064-019-02847-9.
34	MA J， WAN J， MENG J， et al. Methamphetamine induces autophagy as a pro-survival response against apoptotic endothelial cell death through the Kappa opioid receptor[J]. Cell Death Dis，2014，5（3）：e1099. doi：10.1038/cddis.2014.64.
35	ZHANG Y， SHEN K， BAI Y， et al. Mir143-BBC3 cascade reduces microglial survival via interplay between apoptosis and autophagy： Implications for methamphetamine-mediated neurotoxicity[J]. Autophagy，2016，12（9）：1538-1559. doi：10.1080/15548627.2016.1191723.
36	LI J， ZHU L， SU H， et al. Regulation of miR-128 in the nucleus accumbens affects metham-phetamine-induced behavioral sensitization by modulating proteins involved in neuroplasticity[J]. Addict Biol，2021，26（1）：e12881. doi：10.1111/adb.12881.
37	LIU P， LEI G， CHU Z， et al. The role of HINT1 in methamphetamine-induced behavioral sensitization[J]. Psychopharmacology （Berl），2020，237（8）：2345-2351. doi：10.1007/s00213-020-05538-4.
38	CUBELLS J F， RAYPORT S， RAJENDRAN G， et al. Methamphetamine neurotoxicity involves vacuo-lation of endocytic organelles and dopamine-depen-dent intracellular oxidative stress[J]. J Neurosci，1994，14（4）：2260-2271. doi：10.1523/JNEUROSCI.14-04-02260.1994.
39	TOBOREK M， SEELBACH M J， RASHID C S， et al. Voluntary exercise protects against methamphe-tamine-induced oxidative stress in brain microvasculature and disruption of the blood-brain barrier[J]. Mol Neurodegener，2013，8：22. doi：10.1186/1750-1326-8-22.
40	HANSEN J P， RIDDLE E L， SANDOVAL V， et al. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport： Mechanisms and implications for neurotoxicity[J]. J Pharmacol Exp Ther，2002，300（3）：1093-1100. doi：10.1124/jpet.300.3.1093.
41	CADET J L， BRANNOCK C. Free radicals and the pathobiology of brain dopamine systems[J]. Neurochem Int，1998，32（2）：117-131. doi：10.1016/s0197-0186（97）00031-4.
42	BROWN J M， YAMAMOTO B K. Effects of amphetamines on mitochondrial function： Role of free radicals and oxidative stress[J]. Pharmacol Ther，2003，99（1）：45-53. doi：10.1016/s0163-7258（03）00052-4.
43	DENG X， CAI N S， MCCOY M T， et al. Metham-phetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway[J]. Neuropharmacology，2002，42（6）：837-845. doi：10.1016/s0028-3908（02）00034-5.
44	CUNHA-OLIVEIRA T， REGO A C， CARDOSO S M， et al. Mitochondrial dysfunction and caspase activation in rat cortical neurons treated with cocaine or amphetamine[J]. Brain Res，2006，1089（1）：44-54. doi：10.1016/j.brainres.2006.03.061.
45	SAHA K， SAMBO D， RICHARDSON B D， et al. Intracellular methamphetamine prevents the do-pamine-induced enhancement of neuronal firing[J]. J Biol Chem，2014，289（32）：22246-22257. doi：10.1074/jbc.M114.563056.
46	SUN D， YUE Q， GUO W， et al. Neuroprotection of resveratrol against neurotoxicity induced by me-thamphetamine in mouse mesencephalic dopaminergic neurons[J]. Biofactors，2015，41（4）：252-260. doi：10.1002/biof.1221.
47	WARREN M W， ZHENG W， KOBEISSY F H， et al. Calpain- and caspase-mediated αII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure[J]. Int J Neuropsychopharmacol，2007，10（4）：479-489. doi：10.1017/s1461145706007061.
48	WEISSMAN B A， JONES C L， LIU Q， et al. Activation and inactivation of neuronal nitric oxide synthase： Characterization of Ca²⁺-dependent [¹²⁵I]Cal-modulin binding[J]. Eur J Pharmacol，2002，435（1）：9-18. doi：10.1016/S0014-2999（01）01560-6.
49	BROWN G C， COOPER C E. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase[J]. FEBS Lett，1994，356（2/3）：295-298. doi：10.1016/0014-5793（94）01290-3.
50	KIM B， YUN J， PARK B. Methamphetamine-induced neuronal damage： Neurotoxicity and neuroinflammation[J]. Biomol Ther （Seoul），2020，28（5）：381-388. doi：10.4062/biomolther.2020.044.
51	SHAERZADEH F， STREIT W J， HEYSIEAT-TALAB S， et al. Methamphetamine neurotoxicity， microglia， and neuroinflammation[J]. J Neuroinflammation，2018，15（1）：341. doi：10.1186/s12974-018-1385-0.
52	赵蕾. miR-143/PUMA引起NLRP3活化在甲基苯丙胺致神经炎性反应中的作用[D].南京：东南大学，2018.
	ZHAO L. NLRP3 activation regulated by miR-143/PUMA： Implications for methamphetamine-induced neuroinflammatory response[D]. Nanjing： Southeast University，2018.
53	HEINZERLING K G， SHOPTAW S， PECK J A， et al. Randomized， placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence[J]. Drug Alcohol Depend，2006，85（3）：177-184. doi：10.1016/j.drugalcdep.2006.03.019.
54	KOHNO M， DENNIS L E， MCCREADY H， et al. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder[J]. Drug Alcohol Depend，2018，192：186-192. doi：10.1016/j.drugalcdep.2018.07.045.
55	RUNARSDOTTIR V， HANSDOTTIR I， TYR-FINGSSON T， et al. Extended-release injectable naltrexone （XR-NTX） with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment： A placebo-controlled trial[J]. J Addict Med，2017，11（3）：197-204. doi：10.1097/adm.0000000000000297.
56	COFFIN P O， SANTOS G M， HERN J， et al. Extended-release naltrexone for methamphetamine dependence among men who have sex with men： A randomized placebo-controlled trial[J]. Addiction，2018，113（2）：268-278. doi：10.1111/add.13950.
57	FARAHZADI M H， MOAZEN-ZADEH E， RA-ZAGHI E， et al. Riluzole for treatment of men with methamphetamine dependence： A randomized， double-blind， placebo-controlled clinical trial[J]. J Psychopharmacol，2019，33（3）：305-315. doi：10.1177/0269881118817166.
58	MORABBI M J， RAZAGHI E， MOAZEN-ZADEH E， et al. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence： A randomized， double-blind， placebo-controlled clinical trial[J]. Int Clin Psychopharmacol，2018，33（2）：111-119. doi：10.1097/YIC.0000000000000200.
59	KONGSAKON R， PAPADOPOULOS K I， SA-GUANSIRITHAM R. Mirtazapine in amphetamine detoxification： A placebo-controlled pilot study[J]. Int Clin Psychopharmacol，2005，20（5）：253-256. doi：10.1097/01.yic.0000166815.83017.d8.
60	CRUICKSHANK C C， MONTEBELLO M E， DYER K R， et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal[J]. Drug Alcohol Rev，2008，27（3）：326-333. doi：10.1080/09595230801935672.
61	ANDERSON A L， LI S H， MARKOVA D， et al. Bupropion for the treatment of methamphetamine dependence in non-daily users： A randomized， double-blind， placebo-controlled trial[J]. Drug Alcohol Depend，2015，150：170-174. doi：10.1016/j.drugalcdep.2015.01.036.
62	ELKASHEF A M， RAWSON R A， ANDERSON A L， et al. Bupropion for the treatment of metham-phetamine dependence[J]. Neuropsychopharmacology，2008，33（5）：1162-1170. doi：10.1038/sj.npp.1301481.
63	HEINZERLING K G， SWANSON A N， HALL T M， et al. Randomized， placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use[J]. Addiction，2014，109（11）：1878-1886. doi：10.1111/add.12636.
64	SCHOTTENFELD R S， CHAWARSKI M C， SO-FUOGLU M， et al. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment： A randomized controlled trial[J]. Drug Alcohol Depend，2018，186：130-137. doi：10.1016/j.drugalcdep.2018.01.017.
65	COFFIN P O， SANTOS G M， DAS M， et al. Ari-piprazole for the treatment of methamphetamine dependence： A randomized， double-blind， placebo-con-trolled trial[J]. Addiction，2013，108（4）：751-761. doi：10.1111/add.12073.
66	TIIHONEN J， KUOPPASALMI K， FÖHR J， et al. A comparison of aripiprazole， methylphenidate， and placebo for amphetamine dependence[J]. Am J Psychiatry，2007，164（1）：160-162. doi：10.1176/ajp.2007.164.1.160.
67	SU H， SUN T， WANG X， et al. Levo-tetrahy-dropalmatine attenuates methamphetamine reward behavior and the accompanying activation of ERK phosphorylation in mice[J]. Neurosci Lett，2020，714：134416. doi：10.1016/j.neulet.2019.134416.
68	WANG Y， GU Y H， LIU M， et al. Fluoxetine protects against methamphetamine‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats[J]. Mol Med Rep，2017，15（2）：673-680. doi：10.3892/mmr.2016.6072.
69	WU J， ZHU D， ZHANG J， et al. Melatonin treatment during the incubation of sensitization attenuates methamphetamine-induced locomotor sensitization and MeCP2 expression[J]. Prog Neuropsychopharmacol Biol Psychiatry，2016，65：145-152. doi：10.1016/j.pnpbp.2015.09.008.
70	WANG Y， WANG X， CHEN J， et al. Melatonin pretreatment attenuates acute methamphetamine-induced aggression in male ICR mice[J]. Brain Res，2019，1715：196-202. doi：10.1016/j.brainres.2019.04.002.
71	LWIN T， YANG J L， NGAMPRAMUAN S， et al. Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NFκB signaling pathway in the mouse hippocampus[J]. Prog Neuropsychopharmacol Biol Psychiatry，2021，111：110109. doi：10.1016/j.pnpbp.2020.110109.
72	KANTHASAMY K， GORDON R， JIN H， et al. Neuroprotective effect of resveratrol against metham-phetamine-induced dopaminergic apoptotic cell death in a cell culture model of neurotoxicity[J]. Curr Neuropharmacol，2011，9（1）：49-53. doi：10.2174/157015911795017353.
73	MA C L， LI L， YANG G M， et al. Neuroprotective effect of gastrodin in methamphetamine-induced apoptosis through regulating cAMP/PKA/CREB pathway in cortical neuron[J]. Hum Exp Toxicol，2020，39（8）：1118-1129. doi：10.1177/0960327120911438.
74	YANG G M， LI L， XUE F L， et al. The potential role of PKA/CREB signaling pathway concerned with gastrodin administration on methamphe-tamine-induced conditioned place preference rats and SH-SY5Y cell line[J]. Neurotox Res，2020，37（4）：926-935. doi：10.1007/s12640-019-00150-7.
75	薛凤麟，洪仕君，曾晓峰，等. 天麻素注射液通过调节背侧纹状体miR-30a表达改善大鼠甲基苯丙胺成瘾的实验研究[J].中药药理与临床，2020，36（1）：85-89. doi：10.13412/j.cnki.zyyl.2020.01.009.
	XUE F L， HONG S J， ZENG X F， et al. Effect of gastrodin injection on improving methamphe-tamine addiction in rats by regulating the expression of miR-30a in dorsal striatum[J]. Zhongyao Yaoli Yu Linchuang，2020，36（1）：85-89.
76	黄兆奎，石振金，吴亚梅，等. 甲基苯丙胺不同给药时程及天麻素的干预对建立大鼠条件性位置偏爱模型的影响[J].昆明医科大学学报，2019，40（3）：1-5. doi：10.3969/j.issn.1003-4706.2019.03.001.
	HUANG Z K， SHI Z J， WU Y M， et al. Establishment of the methamphetamine induced rat conditioned place preference model and the intervention effect of gastrodin[J]. Kunming Yike Daxue Xuebao，2019，40（3）：1-5.
77	DANG D K， SHIN E J， KIM D J， et al. Ginseno-side Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor[J]. J Neuroinflammation，2018，15（1）：52. doi：10.1186/s12974-018-1087-7.
78	SHIN E J， SHIN S W， NGUYEN T T L， et al. Ginsenoside Re rescues methamphetamine-induced oxidative damage， mitochondrial dysfunction， micro-glial activation， and dopaminergic degeneration by inhibiting the protein kinase Cδ gene[J]. Mol Neurobiol，2014，49（3）：1400-1421. doi：10.1007/s12035-013-8617-1.
79	ZHU C， LIU W， LUO C， et al. Inhibiting effects of rhynchophylline on methamphetamine-dependent zebrafish are related with the expression of tyrosine hydroxylase （TH）[J]. Fitoterapia，2017，117：47-51. doi：10.1016/j.fitote.2017.01.001.
80	陈毅飞，彭菊，房淼，等. 钩藤碱对甲基苯丙胺依赖斑马鱼行为学的影响及机制[J].南方医科大学学报，2016，36（11）：1541-1545. doi：10.3969/j.issn.1673-4254.2016.11.16.
	CHEN Y F， PENG J， FANG M， et al. Effect of rhynchophylline on behaviors of methamphetamine-dependent zebrafish and the mechanism[J]. Nanfang Yike Daxue Xuebao，2016，36（11）：1541-1545.
81	LI J， LIU W， PENG Q， et al. Effect of rhynchophylline on conditioned place preference on expression of NR2B in methamphetamine-dependent mice[J]. Biochem Biophys Res Commun，2014，452（3）：695-700. doi：10.1016/j.bbrc.2014.08.127.
82	XU D D， HOEVEN R， RONG R， et al. Rhynchophylline protects cultured rat neurons against methamphetamine cytotoxicity[J]. Evid Based Complementary Altern Med，2012，2012：636091. doi：10.1155/2012/636091.
83	GONZALEZ-CUEVAS G， MARTIN-FARDON R， KERR T M， et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use： Preclinical proof of principle[J]. Neuropsychopharmacology，2018，43（10）：2036-2045. doi：10.1038/s41386-018-0050-8.
84	HAY G L， BARACZ S J， EVERETT N A， et al. Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methampheta-mine-primed relapse in rats[J]. J Psychopharmacol，2018，32（12）：1369-1378. doi：10.1177/0269881118799954.
85	YANG G， LIU L， ZHANG R， et al. Cannabidiol attenuates methamphetamine-induced conditioned place preference via the Sigma1R/AKT/GSK-3β/CREB signaling pathway in rats[J]. Toxicol Res （Camb），2020，9（3）：202-211. doi：10.1093/toxres/tfaa021.
86	张文怡. 运动影响甲基苯丙胺戒断者ΔFosB和c-Fos血浆水平对渴求程度的改善作用[D].长沙：湖南师范大学，2020.
	ZHANG W Y. Movement influence methampheta-mine withdrawal is ΔFosB plasma levels and c-Fos role on the improvement of the degree of desire[D]. Changsha： Hunan Normal University，2020.
87	李夏雯. 有氧运动对甲基苯丙胺戒断者情绪记忆的影响及机制研究[D].上海：上海体育学院，2020.
	LI X W. The mechanism in the effect of aerobic exercise on emotional memory in methamphetamine abstainers[D]. Shanghai： Shanghai University of Sport，2020.
88	刘瑞雯. 太极拳对上海市女甲基苯丙胺成瘾者执行功能康复效果的研究[D].上海：上海体育学院，2019.
	LIU R W. Study on the effect of Tai Chi on functional rehabilitation of female methamphetamine addicts in Shanghai[D]. Shanghai： Shanghai University of Sport，2019.
89	SU H， LIU Y， YIN D， et al. Neuroplastic changes in resting-state functional connectivity after rTMS intervention for methamphetamine craving[J]. Neuropharmacology，2020，175：108177. doi：10.1016/j.neuropharm.2020.108177.
90	XU X， DING X， CHEN L， et al. The transcranial direct current stimulation over prefrontal cortex combined with the cognitive training reduced the cue-induced craving in female individuals with methamphetamine use disorder： A randomized controlled trial[J]. J Psychiatr Res，2021，134：102-110. doi：10.1016/j.jpsychires.2020.12.056.
91	SCHNEIDER F H. Amphetamine-induced exocytosis of catecholamines from the cow adrenal medulla[J]. J Pharmacol Exp Ther，1972，183（1）：80-89.
92	COURTNEY K E， RAY L A. Methamphetamine： An update on epidemiology， pharmacology， clinical phenomenology， and treatment literature[J]. Drug Alcohol Depend，2014，143：11-21. doi：10.1016/j.dru galcdep.2014.08.003.
93	RAWSON R A， CONDON T P. Why do we need an Addiction supplement focused on methampheta-mine?[J]. Addiction，2007，102（S1）：1-4. doi：10.1111/j.1360-0443.2006.01781.x.
94	HSIEH J H， STEIN D J， HOWELLS F M. The neurobiology of methamphetamine induced psychosis[J]. Front Hum Neurosci，2014，8：537. doi：10.3389/fnhum.2014.00537.
95	MAHONEY J J3RD， THOMPSON-LAKE D G Y， COOPER K，et al. A comparison of impulsivity， depressive symptoms， lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders[J]. J Psychopharmacol，2015，29（1）：50-56. doi：10.1177/0269881114560182.
96	JAVANBAKHT M， SHOPTAW S， RAGSDALE A， et al. Depressive symptoms and substance use： Changes overtime among a cohort of HIV-positive and HIV-negative MSM[J]. Drug Alcohol Depend，2020，207：107770. doi：10.1016/j.drugalcdep.2019.107770.
97	ZHANG J， XIE Y， SU H， et al. Prevalence and correlates of depressive symptoms during early me-thamphetamine withdrawal in Han Chinese population[J]. Drug Alcohol Depend，2014，142：191-196. doi：10.1016/j.drugalcdep.2014.06.021.
98	KAY-LAMBKIN F J， BAKER A L， LEE N M， et al. The influence of depression on treatment for methamphetamine use[J]. Med J Aust，2011，195（3）：S38-S43. doi：10.5694/j.1326-5377.2011.tb03264.x.
99	MCKETIN R， LUBMAN D I， LEE N M， et al. Major depression among methamphetamine users entering drug treatment programs[J]. Med J Aust，2011，195（3）：S51-S55. doi：10.5694/j.1326-5377.2011.tb03266.x.
100	MARAZZITI D， BARONI S， PICCHETTI M， et al. Mitochondrial alterations and neuropsychiatric disorders[J]. Curr Med Chem，2011，18（30）：4715-4721. doi：10.2174/092986711797379221.
101	SUNG Y H， YURGELUN-TODD D A， SHI X F， et al. Decreased frontal lobe phosphocreatine levels in methamphetamine users[J]. Drug Alcohol Depend，2013，129（1/2）：102-109. doi：10.1016/j.drugalcdep.2012.09.015.
102	HELLEM T L， SUNG Y H， SHI X F， et al. Crea-tine as a novel treatment for depression in females using methamphetamine： A pilot study[J]. J Dual Diagn，2015，11（3/4）：189-202. doi：10.1080/15504263.2015.1100471.
103	SILVERSTEIN P S， SHAH A， GUPTE R， et al. Me-thamphetamine toxicity and its implications during HIV-1 infection[J]. J Neurovirol，2011，17（5）：401-415. doi：10.1007/s13365-011-0043-4.
104	PENDYALA G， BUESCHER J L， FOX H S. Methamphetamine and inflammatory cytokines increase neuronal Na⁺/K⁺-ATPase isoform 3： Relevance for HIV associated neurocognitive disorders[J]. PLoS One，2012，7（5）：e37604. doi：10.1371/journal.pone.0037604.
105	MATA M M， NAPIER T C， GRAVES S M， et al. Methamphetamine decreases CD4 T cell frequency and alters pro-inflammatory cytokine production in a model of drug abuse[J]. Eur J Pharmacol，2015，752：26-33. doi：10.1016/j.ejphar.2015.02.002.
106	WANG X， WANG Y， YE L， et al. Modulation of intracellular restriction factors contributes to metham-phetamine-mediated enhancement of acquired immune deficiency syndrome virus infection of macrophages[J]. Curr HIV Res，2012，10（5）：407-414. doi：10.2174/157016212802138797.
107	BELLO K J， MESNER O， O’BRYAN T A， et al. Factors associated with 10 years of continuous viral load suppression on HAART[J]. BMC Infect Dis，2016，16：351. doi：10.1186/s12879-016-1677-x.
108	PARSONS J T， KOWALCZYK W J， BOTSKO M， et al. Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men[J]. AIDS Behav，2013，17（4）：1478-1487. doi：10.1007/s10461-013-0463-7.
109	FAIRBAIRN N， KERR T， MILLOY M J， et al. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users[J]. Addict Behav，2011，36（7）：762-763. doi：10.1016/j.addbeh.2011.02.001.
110	ROBINSON J D， HOWARD C D， PASTUZYN E D， et al. Methamphetamine-induced neurotoxicity disrupts pharmacologically evoked dopamine transients in the dorsomedial and dorsolateral striatum[J]. Neurotox Res，2014，26（2）：152-167. doi：10.1007/s12640-014-9459-y.
111	PREGELJC D， TEODORESCU-PERIJOC D， VIANE-LLO R， et al. How important is the use of cocaine and amphetamines in the development of parkinson disease? A computational study[J]. Neurotox Res，2020，37（3）：724-731. doi：10.1007/s12640-019-00149-0.
112	LAPPIN J M， DARKE S， FARRELL M. Methamphe-tamine use and future risk for Parkinson’s disease： Evidence and clinical implications[J]. Drug Alcohol Depend，2018，187：134-140. doi：10.1016/j.drugalcdep.2018.02.032.
113	KISH S J， BOILEAU I， CALLAGHAN R C， et al. Brain dopamine neurone ‘damage’： Methamphetamine users vs. Parkinson’s disease - a critical assessment of the evidence[J]. Eur J Neurosci，2017，45（1）：58-66. doi：10.1111/ejn.13363.
114	KEVIL C G， GOEDERS N E， WOOLARD M D， et al. Methamphetamine use and cardiovascular disease[J]. Arterioscler Thromb Vasc Biol，2019，39（9）：1739-1746. doi：10.1161/ATVBAHA.119.312461.
115	DARKE S， DUFLOU J， KAYE S. Prevalence and nature of cardiovascular disease in methamphetamine-related death： A national study[J]. Drug Alcohol Depend，2017，179：174-179. doi：10.1016/j.drugalcdep.2017.07.001.
116	REYNOLDS A R， STRICKLAND J C， STOOPS W W， et al. Buspirone maintenance does not alter the reinforcing， subjective， and cardiovascular effects of intranasal methamphetamine[J]. Drug Alcohol Depend，2017，181：25-29. doi：10.1016/j.drugalcdep.2017.08.038.
117	CARVALHO M， CARMO H， COSTA V M， et al. Toxicity of amphetamines： An update[J]. Arch Toxicol，2012，86（8）：1167-1231. doi：10.1007/s00204-012-0815-5.
118	RAMIREZ R L3RD， PEREZ V J， ZAMANIAN R T. Methamphetamine and the risk of pulmonary arterial hypertension[J]. Curr Opin Pulm Med，2018，24（5）：416-424. doi：10.1097/mcp.0000000000000513.
119	孙晓宇，王玉，李竹，等. 缝隙连接蛋白43及其S368位点磷酸化水平与甲基苯丙胺诱导的心肌毒性的关系[J].中国动脉硬化杂志，2019，27（5）：374-380. doi：10.3969/j.issn.1007-3949.2019.05.003.
	SUN X Y， WANG Y， LI Z， et al. Relationship between connexin 43 and phosphorylation of its S368 site and methamphetamine induced myocardial toxicity[J]. Zhongguo Dongmai Yinghua Zazhi，2019，27（5）：374-380.
120	SUN X， WANG Y， XIA B， et al. Methampheta-mine produces cardiac damage and apoptosis by decreasing melusin[J]. Toxicol Appl Pharmacol，2019，378：114543. doi：10.1016/j.taap.2019.03.015.
121	华楠，张玉荣，沈舜义. 毒品的快速检测方法开发及其应用[J].世界临床药物，2016，37（3）：210-213. doi：10.13683/j.wph.2016.03.015.
	HUA N， ZHANG Y R， SHEN S Y. Development and application of rapid drug detection[J]. Shijie Linchuang Yaowu，2016，37（3）：210-213.
122	郝红霞，白凤波. 甲基苯丙胺检测方法研究进展[J].分析试验室，2020，39（3）：364-372. doi：10.13595/j.cnki.issn1000-0720.2019.110605.
	HAO H X， BAI F B. Advances in the detection of methamphetamine[J]. Fenxi Shiyanshi，2020，39（3）：364-372.
123	魏万里. SPE-GC-MS/MS-SRM法快速检测尿液中12种常见毒品成分及代谢物[J].中国人民公安大学学报（自然科学版），2012，18（3）：27-31. doi：10.3969/j.issn.1007-1784.2012.03.008.
	WEI W L. Rapid detection of 12 common drug components and metabolites in urine by SPE-GC-MS/MS-SRM[J]. Zhongguo Renmin Gongan Daxue Xuebao （Natural science edition），2012，18（3）：27-31.
124	YANG Y， WU J， DENG J， et al. Rapid and on-site analysis of amphetamine-type illicit drugs in whole blood and raw urine by slug-flow microextraction coupled with paper spray mass spectrometry[J]. Anal Chim Acta，2018，1032：75-82. doi：10.1016/j.aca.2018.
06	006.
125	STEUER A E， SCHMIDHAUSER C， LIECHTI M E， et al. Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methy-lenedioxy-methamphetamine （MDMA） and its phase Ⅰ and Ⅱ metabolites in human blood plasma[J]. Drug Test Anal，2015，7（7）：592-602. doi：10.1002/dta.1740.
126	SHU I， ALEXANDER A， JONES M， et al. Determination of methamphetamine enantiomer composition in human hair by non-chiral liquid chro-matography-tandem mass spectrometry method[J]. J Chromatogr B Analyt Technol Biomed Life Sci，2016，1028：145-152. doi：10.1016/j.jchromb.2016.06.015.
127	唐晓欢，吴天辉，孙荣基，等. 胶体金试纸法检测头发样本中吗啡和甲基苯丙胺的准确性及可靠性研究[J].国际药学研究杂志，2020，47（10）：876-880. doi：10.13220/j.cnki.jipr.2020.10.018.
	TANG X H， WU T H， SUN R J， et al. The accuracy and reliability of colloidal gold lateral assay in detection of morphine and methamphetamine in hair samples[J]. Guoji Yaoxue Yanjiu Zazhi，2020，47（10）：876-880.
128	赵绪龙，马广鹏，武继锋，等. 冷冻研磨结合LC-MS/MS法检测指甲中甲基苯丙胺、苯丙胺成分[J].刑事技术，2020，45（6）：601-605. doi：10.16467/j.1008-3650.2020.06.011.
	ZHAO X L， MA G P， WU J F， et al. Determination of methamphetamine and amphetamine in nail through frozen grinding coupled into high performance liquid chromatography-tandem mass spectrometry[J]. Xingshi Jishu，2020，45（6）：601-605.
129	吴元钊，吕云平，王继业. 基于表面等离子共振技术的毒品快检装备设计与开发[J].警察技术，2020（1）：89-91. doi：10.3969/j.issn.1009-9875.2020.01.023.
	WU Y Z， LÜ Y P， WANG J Y. Design and development of drug rapid detection equipment based on surface plasmon resonance technology[J]. Jingcha Jishu，2020（1）：89-91.
130	MCGEEHAN J， DENNANY L. Electrochemiluminescent detection of methamphetamine and amphe-tamine[J]. Forensic Sci Int，2016，264：1-6. doi：10.1016/j.forsciint.2016.02.048.
131	WANG J， YAO W， MENG F， et al. A surface plasmon resonance immunoassay for the rapid analysis of methamphetamine in forensic oral fluid[J]. J Clin Lab Anal，2019，33（9）：e22993. doi：10.1002/jcla.22993.
132	XUE W， TAN X， KHAING OO M K， et al. Rapid and sensitive detection of drugs of abuse in sweat by multiplexed capillary based immuno-biosensors[J]. Analyst，2020，145（4）：1346-1354. doi：10.1039/c9an02498k.

[1]	Wen LI, Hao-zhe LI, Chen CHEN, Wei-xiong CAI. Research Progress and Application Prospect of Facial Micro-Expression Analysis in Forensic Psychiatry [J]. Journal of Forensic Medicine, 2023, 39(5): 493-500.
[2]	Zhong-hua WANG, Shu-jin LI. Research Progress on Molecular Biology of Human Height Estimation [J]. Journal of Forensic Medicine, 2023, 39(5): 487-492.
[3]	Cui-mei LIU, Wei JIA, Chun-hui SONG, Zhen-hua QIAN, Zhen-dong HUA, Yue-meng CHEN. Qualitative and Quantitative Analysis of Five Indoles or Indazole Amide Synthetic Cannabinoids in Suspected E-Cigarette Oil by GC-MS [J]. Journal of Forensic Medicine, 2023, 39(5): 457-464.
[4]	Lu CHEN, Zhe ZHOU, Sheng-qi WANG. Process of Forensic Medicine in DNA Identification of Aged Human Remains [J]. Journal of Forensic Medicine, 2023, 39(5): 478-486.
[5]	Yong ZENG, Dong-hua ZOU, Ying FAN, Qing XU, Lu-yang TAO, Yi-jiu CHEN, Zheng-dong LI. Research Progress and Forensic Application of Human Vascular Finite Element Modeling and Biomechanics [J]. Journal of Forensic Medicine, 2023, 39(5): 471-477.
[6]	Wen-ya ZHAI, Li-na WU, Shuo YANG, Bao-hua SHEN, Yan SHI. Detection and Analysis of Blood Dexmedetomidine in Drug-Facilitated Cases [J]. Journal of Forensic Medicine, 2023, 39(5): 452-456.
[7]	Fei FAN, Juan WU, Zhen-hua DENG. Application Progress of Objective Audiological Detection Techniques in Forensic Clinical Medicine [J]. Journal of Forensic Medicine, 2023, 39(4): 360-366.
[8]	Qing-qing XIANG, Li-fang CHEN, Qin SU, Yu-kun DU, Pei-yan LIANG, Xiao-dong KANG, He SHI, Qu-yi XU, Jian ZHAO, Chao LIU, Xiao-hui CHEN. Research Progress on Microbial Community Succession in the Postmortem Interval Estimation [J]. Journal of Forensic Medicine, 2023, 39(4): 399-405.
[9]	Yu-qi CAO, Yan SHI, Ping XIANG, Yin-long GUO. Research Progress on Machine Learning Assisted Non-Targeted Screening Strategy for Identification of Fentanyl Analogs [J]. Journal of Forensic Medicine, 2023, 39(4): 406-416.
[10]	Ran LI, Hong-yu SUN. Methods and Research Hotspots of Forensic Kinship Testing [J]. Journal of Forensic Medicine, 2023, 39(3): 231-239.
[11]	Xiao-yan MA, Hong-yu SUN, Qing LI. Research Progresses of Tri-Allelic Patterns in Autosomal STR in Forensic DNA Analysis [J]. Journal of Forensic Medicine, 2023, 39(3): 240-246.
[12]	Hang CHEN, Jing HU, Zheng QIAO, Hong-xiao DENG, Min LÜ, Wei LIU. Research Progress on Biological Matrix Reference Materials in Forensic Toxicology [J]. Journal of Forensic Medicine, 2023, 39(2): 176-185.
[13]	Hong-yan GAO, Guang-fu LIU, Jian WU, Peng-yu CHEN. Animal DNA Typing and Its Research Progress in Forensic Medicine [J]. Journal of Forensic Medicine, 2023, 39(2): 161-167.
[14]	Wu LONG, Peng-fei QU, Lin MA, Rui WANG, Yan-mei XI, Yu-hua LI, Sheng-jie NIE, Ting DUAN, Jin-liang DU, Xue TANG, Jing-feng ZHAO, Pu-ping LEI, Yue-bing WANG. Cytotoxicity of 4 Wild Mushrooms in a Case of Yunnan Sudden Unexplained Death [J]. Journal of Forensic Medicine, 2023, 39(2): 121-128.
[15]	Zhong-ping CHENG, Yan-fei LIU, Xing-min XU, Yao-nan MO. Progress in the Application of Magnetic Nanoparticles in Forensic Trace Analysis [J]. Journal of Forensic Medicine, 2023, 39(2): 168-175.